Table 1 Healthy control and patient characteristics
From: Platelet adhesion in type 2 diabetes: impact of plasma albumin and mean platelet volume
Demographical and laboratory data | Healthy controls (n = 60) | Type 2 diabetic patients (n = 60) |
|---|---|---|
Female/Male sex (n) | 28/32 | 28/32 |
Age, years (mean ± SD) | 60.1 ± 3.5 | 60.8 ± 3.5 |
Platelet count, 109/L (mean ± SD) | 210.5 ± 103.3 | 200.1 ± 83.7 |
P-Magnesium, mmol/L (mean ± SD) | 0.85 ± 0.07 | 0.82 ± 0.08 |
P-Albumin, g/L (mean ± SD) | 41.6 ± 2.9 | 41.0 ± 3.7 |
Therapy at admission (n) | ||
Insulin | - | 19 |
Peroral antidiabetics | - | 37 |
Acetylsalicylic acid (ASA) | - | 16 |
Anticoagulants or Platelet inhibitor (other than ASA) | - | 2 |
Anti-inflammatory drugs | - | 3 |
ACE inhibitors | - | 16 |
Angiotensin receptor blockers (ARB) | - | 5 |
Beta blockers | - | 16 |
Calcium antagonists | - | 7 |
Diuretics | - | 14 |
Statins | - | 29 |
Selective serotonin reuptake inhibitors (SSRI) | - | 4 |
Bensodiazepines | - | 1 |